Sousa EDJSD, Sousa GCD, Baia VF, Somensi DN, Xavier MB. Botulinum toxin type A in chronic neuropathic pain in refractory leprosy.
ARQUIVOS DE NEURO-PSIQUIATRIA 2019;
77:346-351. [PMID:
31188999 DOI:
10.1590/0004-282x20190053]
[Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/18/2018] [Accepted: 03/20/2019] [Indexed: 11/22/2022]
Abstract
OBJECTIVE
Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication.
METHODS
We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60.
RESULTS
Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL.
CONCLUSION
BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients.
Collapse